Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas

Treatment of patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphoma remains an unmet clinical need, and the progressive myocardial toxicity related to cumulative, dose-dependent damage induced by anthracyclines represents a tricky issue in the planning of therapy. Pixantrone is a promising aza-anthracenedione with reduced cardiotoxicity and significant antineoplastic activity, and has been investigated in solid and hematologic tumors in several Phase I, II, and III trials. The aim of this review is to summarize the data reported so far on pixantrone as a salvage therapy in relapsed/refractory non-Hodgkin B-cell lymphoma.

• Publication year

  2014

• Venue

  OncoTargets and Therapy

• Publication date

  2014-05-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/OTT.S34055PMID 24926199PMCID 4049882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.

  2013cited by this paper
• Anthracycline-containing regimens for treatment of follicular lymphoma in adults.

  2013cited by this paper
• The Novel Anthracenedione, Pixantrone, Lacks Redox Activity and Inhibits Doxorubicinol Formation in Human Myocardium: Insight to Explain the Cardiac Safety of Pixantrone in Doxorubicin-Treated Patients

  2013cited by this paper
• The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.

  2013cited by this paper
• Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.

  2012cited by this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cited by this paper
• Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma

  2011cited by this paper
• Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

  2010cited by this paper
• New developments in anthracycline-induced cardiotoxicity.

  2009cited by this paper
• Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group

  2008cited by this paper
• A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma

  2007cited by this paper
• Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

  2007cited by this paper
• Congestive heart failure in patients treated with doxorubicin

  2003cited by this paper
• Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.

  2003cited by this paper
• Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma.

  2003cited by this paper
• Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.

  2001cited by this paper
• Human Heart Cytosolic Reductases and Anthracycline Cardiotoxicity

  2001cited by this paper
• A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.

  2001cited by this paper
• Bbr 2778, an Aza-anthracenedione Endowed with Preclinical Anticancer Activity and Lack of Delayed Cardiotoxicity

  2001cited by this paper
• Molecular basis of anthracycline-induced cardiotoxicity and its prevention.

  2000cited by this paper
• Doxorubicin-Induced Cardiomyopathy

  2000cited by this paper
• A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

  2000cited by this paper
• Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.

  1999cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper
• Doxorubicin-induced cardiomyopathy.

  1998cited by this paper
• Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.

  1995cited by this paper
• Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

  1995cited by this paper
• Aza and diaza bioisosteric anthracene-9,10-diones as antitumor agents.

  1995cited by this paper
• Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells.

  1995cited by this paper
• Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones.

  1995cited by this paper
• Anthracene-9,10-Diones and Aza Bioisosteres as Antitumor Agents

  1995cited by this paper
• ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

  1994cited by this paper
• Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II.

  1993cited by this paper
• Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells.

  1990cited by this paper
• Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

  1988cited by this paper
• Risk factors for doxorubicin-induced congestive heart failure.

  1979cited by this paper

• Fluorescent properties of FDA-approved anti-leukemia drugs

  2025cites this paper
• Encapsulation of pixantrone into PEGylated liposomes enhances its antineoplastic efficacy and reduces thymus toxicity

  2023cites this paper
• Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection

  2021cites this paper
• Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma

  2021cites this paper
• Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma

  2020cites this paper
• A Survey of Synthetic Routes and Antitumor Activities for Benzo[g]quinoxaline-5,10-diones

  2020cites this paper
• The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.

  2019cites this paper
• Pixantrone beyond monotherapy: a review

  2019cites this paper
• Pixantrone: novel mode of action and clinical readouts

  2018cites this paper
• Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial

  2018influential citation
• Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells

  2018cites this paper
• Pixantrone in relapsed or refractory aggressive non-Hodgkin’s lymphoma: a guide to its use

  2017cites this paper
• The Servier oncology pipeline in 2017.

  2017cites this paper
• Pixantrone in relapsed or refractory aggressive non-Hodgkin’s lymphoma: a guide to its use

  2017cites this paper
• Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial

  2016cites this paper
• Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma

  2016cites this paper
• Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.

  2016cites this paper
• In silico designing, cloning, and heterologous expression of novel chimeric human B lymphocyte CD20 extra loop

  2016cites this paper
• Pixantrone dimaleate for treating non-Hodgkin’s lymphoma

  2015cites this paper